Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07311057) titled 'Investigation of Effect of Formulated Methylene Blue on Treatment of Squamous Cell Carcinoma Skin Cancer in Inoperable Patients and Not Suitable for Radiotherapy' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Daryoush Hamidi Alamdari, PhD
Condition:
SCC - Squamous Cell Carcinoma
SCC - Squamous Cell Carcinoma of Skin
Inoperable Disease
Intervention:
Drug: Formulated Topical Methylene Blue (0.5 mg/mL)
Recruitment Status: Recruiting
Phase: Phase 3
Date of First En...